{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T14:07:13Z","timestamp":1789913233276,"version":"4.0.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2005,8,1]],"date-time":"2005-08-01T00:00:00Z","timestamp":1122854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Urology"],"published-print":{"date-parts":[[2005,8]]},"DOI":"10.1016\/j.urology.2005.03.052","type":"journal-article","created":{"date-parts":[[2005,7,26]],"date-time":"2005-07-26T18:59:34Z","timestamp":1122404374000},"page":"461-466","source":"Crossref","is-referenced-by-count":46,"title":["Intravesical interleukin-12 gene therapy in an orthotopic bladder cancer model"],"prefix":"10.1016","volume":"66","author":[{"given":"Minoru","family":"Horinaga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelley M.","family":"Harsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuichi","family":"Fukuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren","family":"Heston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Larchian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2005.03.052_bib1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3322\/canjclin.54.1.8","article-title":"Cancer statistics, 2004","volume":"54","author":"Jemal","year":"2004","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urology.2005.03.052_bib2","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJM199004193221607","article-title":"Biology and management of bladder cancer","volume":"322","author":"Raghavan","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2005.03.052_bib3","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0094-0143(05)70238-X","article-title":"The potential role of gene therapy in the treatment of bladder cancer","volume":"27","author":"Hsieh","year":"2000","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.urology.2005.03.052_bib4","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/0952-7915(93)90128-F","article-title":"Non-antibody immunotherapy of cancer","volume":"5","author":"Chapman","year":"1993","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.urology.2005.03.052_bib5","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1097\/01.ju.0000073852.24341.4a","article-title":"Immune mechanisms in bacillus Calmette-Gu\u00e9rin immunotherapy for superficial bladder cancer","volume":"170","author":"Bohle","year":"2003","journal-title":"J Urol"},{"issue":"suppl 3","key":"10.1016\/j.urology.2005.03.052_bib6","doi-asserted-by":"crossref","first-page":"S106","DOI":"10.1086\/314065","article-title":"Role of animal models in understanding intravesical therapy with bacille Calmette-Gu\u00e9rin","volume":"31","author":"Ratliff","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.urology.2005.03.052_bib7","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S0022-5347(17)35678-1","article-title":"T-cell subsets required for intravesical BCG immunotherapy for bladder cancer","volume":"150","author":"Ratliff","year":"1993","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2005.03.052_bib8","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/S0140-6736(98)07422-4","article-title":"BCG immunotherapy of bladder cancer","volume":"353","author":"Alexandroff","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.urology.2005.03.052_bib9","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1046\/j.1365-2249.2002.01734.x","article-title":"IFN-gamma and IL-12 but not IL-10 are required for local tumour surveillance in a syngeneic model of orthotopic bladder cancer","volume":"127","author":"Riemensberger","year":"2002","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.urology.2005.03.052_bib10","first-page":"3399","article-title":"Injection of complementary DNA encoding interleukin-12 inhibits tumor establishment at a distant site in a murine renal carcinoma model","volume":"56","author":"Tan","year":"1996","journal-title":"Cancer Res"},{"key":"10.1016\/j.urology.2005.03.052_bib11","doi-asserted-by":"crossref","first-page":"351","DOI":"10.4049\/jimmunol.159.1.351","article-title":"Eradication of murine bladder carcinoma by intratumor injection of a bicistronic adenoviral vector carrying cDNAs for the IL-12 heterodimer and its inhibition by the IL-12 p40 subunit homodimer","volume":"159","author":"Chen","year":"1997","journal-title":"J Immunol"},{"key":"10.1016\/j.urology.2005.03.052_bib12","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/sj.cgt.7700375","article-title":"Combined IL-12 and GM-CSF gene therapy for murine hepatocellular carcinoma","volume":"8","author":"Wang","year":"2001","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.urology.2005.03.052_bib13","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1089\/hum.1998.9.4-457","article-title":"Construction of vectors expressing bioactive heterodimeric and single-chain murine interleukin-12 for gene therapy","volume":"9","author":"Lee","year":"1998","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.urology.2005.03.052_bib14","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/sj.cgt.7700469","article-title":"A cancer gene therapy approach through translational control of a suicide gene","volume":"9","author":"DeFatta","year":"2002","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.urology.2005.03.052_bib15","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1016\/S0021-9258(17)41980-6","article-title":"Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations","volume":"269","author":"Felgner","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1016\/j.urology.2005.03.052_bib16","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/sj.gt.3301157","article-title":"Intravesical liposome-mediated interleukin-2 gene therapy in orthotopic murine bladder cancer model","volume":"7","author":"Horiguchi","year":"2000","journal-title":"Gene Ther"},{"key":"10.1016\/j.urology.2005.03.052_bib17","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s002620050578","article-title":"Synergistic antitumor effects of interleukin-12 gene transfer and systemic administration of interleukin-18 in a mouse bladder cancer model","volume":"48","author":"Yamanaka","year":"1999","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.urology.2005.03.052_bib18","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/0090-4295(91)80166-5","article-title":"Long-term complete remission in bladder carcinoma in situ with intravesical TICE bacillus Calmette Gu\u00e9rin","volume":"38","author":"De Jager","year":"1991","journal-title":"Urology"},{"key":"10.1016\/j.urology.2005.03.052_bib19","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1097\/01.ju.0000109742.88380.a2","article-title":"Interleukin-12 immunotherapy of murine transitional cell carcinoma of the bladder","volume":"171","author":"O\u2019Donnell","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2005.03.052_bib20","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(01)61607-0","article-title":"5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Gu\u00e9rin in patients with superficial bladder carcinoma","volume":"161","author":"Malmstrom","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2005.03.052_bib21","first-page":"2216","article-title":"Enhanced induction of very late antigen 4\/lymphocyte function-associated antigen 1-dependent T-cell migration to tumor sites following administration of interleukin 12","volume":"57","author":"Ogawa","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/j.urology.2005.03.052_bib22","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1084\/jem.178.4.1223","article-title":"Antitumor and antimetastatic activity of interleukin 12 against murine tumors","volume":"178","author":"Brunda","year":"1993","journal-title":"J Exp Med"},{"key":"10.1016\/j.urology.2005.03.052_bib23","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.4049\/jimmunol.153.4.1697","article-title":"Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production","volume":"153","author":"Nastala","year":"1994","journal-title":"J Immunol"},{"key":"10.1016\/j.urology.2005.03.052_bib24","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/S0022-5347(05)67677-X","article-title":"Antitumor activity of interleukin-12 against murine bladder cancer","volume":"163","author":"Eto","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2005.03.052_bib25","first-page":"56","article-title":"Postoperative administration of interleukin-12 significantly enhances the anti-tumor immune response of MBT-2 bladder cancer bearing mice","volume":"24","author":"Tzai","year":"2000","journal-title":"Proc Natl Sci Counc Repub China B"},{"key":"10.1016\/j.urology.2005.03.052_bib26","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1097\/01.ju.0000109751.60921.da","article-title":"The essential role of interferon-gamma during interleukin-12 therapy for murine transitional cell carcinoma of the bladder","volume":"171","author":"O\u2019Donnell","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2005.03.052_bib27","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0094-0143(05)70242-1","article-title":"Interleukin-12","volume":"27","author":"Clinton","year":"2000","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.urology.2005.03.052_bib28","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/32801","article-title":"Human gene therapy","volume":"392","author":"Anderson","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.urology.2005.03.052_bib29","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/sj.gt.3301704","article-title":"Intraperitoneal gene delivery mediated by a novel cationic liposome in a peritoneal disseminated ovarian cancer model","volume":"9","author":"Lee","year":"2002","journal-title":"Gene Ther"},{"key":"10.1016\/j.urology.2005.03.052_bib30","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/sj.cgt.7700090","article-title":"Biodistribution of an adenoviral vector carrying the luciferase reporter gene following intravesical or intravenous administration to a mouse","volume":"6","author":"Wood","year":"1999","journal-title":"Cancer Gene Ther"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429505003651?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429505003651?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T21:05:52Z","timestamp":1683147952000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429505003651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,8]]}},"alternative-id":["S0090429505003651"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2005.03.052","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2005,8]]}}}